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Abstract
Background: The prognostic value of grading in breast cancer can be increased with microarray technology, but
proposed strategies are disadvantaged by the use of specific training data or parallel microscopic grading. Here,
we investigate the performance of a method that uses no information outside the breast profile of interest.
Results: In 251 profiled tumours we optimised a method that achieves grading by comparing rank means for
genes predictive of high and low grade biology; a simpler method that allows for truly independent estimation of
accuracy. Validation was carried out in 594 patients derived from several independent data sets. We found that
accuracy was good: for low grade (G1) tumors 83- 94%, for high grade (G3) tumors 74- 100%. In keeping with aim
of improved grading, two groups of intermediate grade (G2) cancers with significantly different outcome could be
discriminated.
Conclusion: This validates the concept of microarray-based grading in breast cancer, and provides a more practical
method to achieve it. A simple R script for grading is available in an additional file. Clinical implementation could
achieve better estimation of recurrence risk for 40 to 50% of breast cancer patients.
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Background
Decisions regarding medical treatment in early breast
cancer are guided by disease stage, morphological char-
acteristics (microscopic grading), and selected biological
factors - notably expression of oestrogen and progester-
one receptors and the HER2 oncogene [1]. The prognos-
tic and therapy-predictive accuracies of these factors are
limited, resulting in over- and under-treatment of
patients. A decade of experience from large scale gene
expression studies have underscored the relevance of
some factors, as well as indicated potential improve-
ments. Retrospective data reveal a high degree of con-
cordance between microarray-technology and
established methods for determining oestrogen and pro-
gesterone receptor status [2-5], as well as expression of
the HER2 oncogene [6]. Concerning histopathological
grading, two studies have indicated a potential for
improvement. Here, the intermediate grade (G2) seems
to lack a biological correlate. Both gene expression-wise
and with regards to prognosis approximately two-thirds
of G2-tumors are similar to the low grade group
whereas about one third resemble the high grade group
[7,8], which means that 40-50% of breast cancer patients
currently get an unnecessarily imprecise estimate of
their risk of recurrence.
For research as well as clinical purposes, we have been
interested to use proposed methods for microarray-
based grading. The more extensively investigated
method [8] - now commercially available through Map-
Quant Dx - involves calculation of a summary score
from genes with increased expression in G1 and G3
cancers, respectively (weighted -1 and +1). To allow use
across different microarray platforms, scores are trans-
formed with scale and offset terms, calculated utilizing
known microscopic grading in data to be classified, in a
leave-one-out cross-validation. It is unclear if the leave-
one-out approach adequately deals with the obvious risk
of over-fitting, and the need for parallel microscopic
grading is not appealing, rendering the method unprac-
tical and insufficiently validated. The methods proposed
by Ivshina et al [7] - prediction analysis of microarrays
(PAM) and statistically weighted syndromes (SWS) -
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data for true reproduction, which is cumbersome and
may deter potential users. Also, data to be classified
may have to be normalized to training data to maintain
accuracy. To validate and simplify the concept of micro-
array-based grading, we tested a method that only uses
information contained in the single tumour profile of
interest.
Implementation
For Sotiriou’s et. al. [8] set of 128 probe sets, the ranks
(1 for a probe set with lowest expression in a given
tumour profile, n for a gene with highest; n = number
of probe sets on the microarray platform) were averaged
for probe sets with increased expression in G3-tumors
(n = 112), and those with increased expression in G1-
tumors (n = 16), respectively. The higher average deter-
mines the genomic grade (we use Sotiriou’sa n dc o -
workers term to distinguish from histopathological
grade). Expression of grade-related genes is thus only
related to other genes internal to the profile, resulting in
a method that can classify individual profiles with no
further information. Insensitivity to data set composi-
t i o n ,n or e q u i r e m e n tf o rt r a i n i n gd a t a ,a n du n b i a s e d
estimation of accuracy are key advantages. Sensitivity to
differences in average expression between probes is a
potential limitation.
Results
We tested the rank-based algorithm in a data set with
251 histopathologically graded breast cancers, here
referred to as the Uppsala data set [9]. An assumption
of equal average rank for G3-probe sets compared to
G1-probe sets was not met: G1-probe sets had higher
average expression than G3-probe sets. This resulted in
bias towards low genomic grade classification calls; we
therefore removed 37 lowly expressed genes from the
larger group (G3-probe sets). With this optimization
performed in the Uppsala cohort, we went on and vali-
dated the method in independent data (Table 1). Con-
siderable accuracy was apparent in these published data
sets - for the three series run on Affymetrix chip tech-
n o l o g y ,9 3 % ,9 4 % ,a n d8 3 %o f( h i s t o p a t h o l o g i c a l )g r a d e
1 tumours were correctly classified as low grade, and
85%, 100%, and 93% of (histopathological) grade 3
tumours were appropriately identified as high grade,
translating to an overall accuracy of 88%, 97% and 88%
for the Stockholm [10], Guys Hospital [11], and Oxford
data [11]. The accuracy for the Netherlands Cancer
Institute (NKI) data was somewhat inferior with an
overall accuracy of 78%, possibly reflecting the fact that
Agilent two-colour technology had been used [12]. The
improvement in prognostic accuracy is illustrated in Fig-
ure 1: with array-based grading histologic G2 tumours
(associated with intermediate outcome) are reclassified
as either genomic G1 or G3 (associated with favourable
or worse outcome, respectively). Further comparisons of
original and simplified expression-based grading calls,
microscopic grading calls, outcome, and unsupervised
clustering results, can be found in Additional file 1.
Conclusions
Routine use of microarray or other RNA-profiling technol-
o g yi ne a r l yb r e a s tc a n c e ri sal i k e l yf u t u r ed e v e l o p m e n t ,
and projects to test this clinically are underway. Common
to all these efforts is the aim to achieve improved prognos-
tic and treatment predictive information. We take particu-
lar interest in microarray-based grading as it offers some
key advantages over other proposed strategies (Mamma-
Print and Oncotype Dx etcetera): grade is well-known and
interpretation in relation to clinical guidelines is straight-
forward. Change of practice - with the potential to spare
patients from aggressive therapy - is likely to happen faster
than with signatures introducing new taxonomies with
unclear relationships to established prognostic and treat-
ment predictive markers. Focusing on factors of known
importance - like grade - also makes it possible to moti-
vate microarray technology as an improvement in medical
technology: similar or improved information (compared to
that contributed by the pathology department) can be
achieved at a competitive cost. Suggested methods to
achieve this - in their current published form [7,8] - are
disadvantaged by methodological complexity and uncer-
tain independent accuracy, which has motivated us to
design a simpler data set-independent method and evalu-
ate it in several tumour series. This can hopefully increase
interest in the concept of microarray-based grading; an R
Table 1 Agreement in classification between microarray-
based and microscopic grading in five published data
sets
Histo-patological grade
Cohort Genomic grade G1 G2 G3
Uppsala G1 63 (93%) 80 (62%) 4 (7.3%)
( N = 251) G3 5 (7.4%) 48 (38%) 51 (93%)
Stockholm G1 26 (93%) 44 (76%) 9 (15%)
( N = 147) G3 2 (7.1%) 14 (24%) 52 (85%)
Guys Hospital G1 16 (94%) 16 (43%) 0
(N = 70) G3 1 (5.9%) 21 (57%) 16 (100%)
Oxford G1 15 (83%) 24 (48%) 1 (7.1%)
(N = 82) G3 3 (17%) 26 (52%) 13 (93%)
NKI G1 64 (85%) 68 (67%) 31 (26%)
(N = 295) G3 11 (15%) 33 (33%) 88 (74%)
In bold: concordance in low and high grade (G1 and G3) assignments,
describing the accuracy of microarray-based grading. Per cent per column
and data set. Genomic grade determined with the optimized signature
(reduced from 128 to 91 probe sets) and mean rank. NKI, the Netherlands
Cancer Institute.
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Page 2 of 4Figure 1 Prognostic significance of microarray-based grading. Tumours in the respective data sets graded with either the “genomic grade”
(green- red) or by a pathologist (solid, dashed and dotted). Fraction of patients alive without distant metastasis (DMFS; y-axis), years (x-axis).
Genomic grade determined with the optimized signature (reduced from 128 to 91 probe sets) and mean rank. P-values = log-rank test of
difference for intermediate grade tumors (hist. G2; dashed line), when stratified by microarray-based grading. Insufficient statistical power in C
and D: the number of events per groups small.
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Page 3 of 4script for the necessary calculations is available in an addi-
tional file (Additional file 2).
Availability and requirements
￿ Project name: expression grade.txt
￿ Project home page: available as an additional file
(Additional file 2)
￿ Operating system(s): any setting where R works
￿ Programming language: R (http://www.r-project.
org/)
￿ Other requirements: none
￿ License: GNU GPL (R)
￿ Any restrictions to use by non-academics: none
Additional material
Additional file 1: Additional analyses and methods. comparisons of
original expression-based grading calls and grade (Table S1), original and
simplified calls (Table S2), outcome (Figure S1), unsupervised clustering
results (Table S3), expanded materials and methods, and R script
instructions.
Additional file 2: Expression grade.txt. An R script for calculation of
the simplified expression-based grade.
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